The Great Peptide Debate, SpaceX's Lunar Mass Driver, AI Coming for Zuck's Job | Martin Shkreli & Max Marchione, Mitchell Green, Shane Hegde, Dr. Adam Oskowitz, Robin Vince, David Senra

March 23, 2026 • 3 hr 2 min

🎧 Listen Now

🤖 AI Summary

Overview

This episode dives into SpaceX's ambitious lunar mass driver project, the evolving role of AI in creative and medical industries, and the contentious debate over peptides. Featuring Martin Shkreli, Max Marchione, Mitchell Green, Shane Hegde, Dr. Adam Oskowitz, Robin Vince, and David Senra, the discussions explore innovation, regulation, and the future of technology and health.

Notable Quotes

- Why do we have to redefine semantics that have been defined forever? Medicine has progressed dramatically thanks to the capitalist system and the biopharmaceutical industry. - Martin Shkreli, on the risks of DIY peptide use.

- AI will never replace creative work. Creative work is deeply illogical, subjective, and starves for perfection all at the same time. - Shane Hegde, on the irreplaceable human element in creativity.

- We're going to look back on 2026 as the year every business in the world was up for grabs because of AI. - Tobi Lütke, as quoted by David Senra, on AI's transformative potential.

🚀 SpaceX's Lunar Mass Driver

- SpaceX unveiled plans for a lunar mass driver, an electromagnetic launch system designed to send payloads from the moon into space.

- The project requires solving challenges like lunar construction, energy storage, and material transport, with timelines ranging from 15 to 75 years debated by participants.

- John Coogan and Jordi Hays discussed the feasibility and historical parallels, comparing it to ambitious projects like the Wright brothers' invention of flight.

💊 The Great Peptide Debate

- Martin Shkreli argued that peptides should follow rigorous FDA approval processes to ensure safety and efficacy, criticizing the gray market for pirated and unverified drugs.

- Max Marchione countered, advocating for legalizing certain peptides to reduce harm and meet growing consumer demand, citing anecdotal evidence of their benefits.

- The debate highlighted broader tensions between innovation, regulation, and consumer health optimization.

📈 SaaS Resilience and Fundraising Insights

- Mitchell Green of Lead Edge Capital shared insights on their $3.5 billion Fund 7, emphasizing the enduring value of enterprise software despite SaaS apocalypse fears.

- Green highlighted the stickiness of software solutions, the importance of customer support, and the role of private equity in driving innovation.

- He also discussed the impact of AI on industries like automotive and logistics, predicting significant disruption across sectors.

🎨 AI in Creative Work

- Shane Hegde introduced Air's new AI-powered features, including a canvas editor, automated agents, and a context layer for brand consistency.

- He emphasized that while AI enhances efficiency, it cannot replace the subjective and perfection-driven nature of creative work.

- Hegde's campaign, AI will never smoke a cigarette with you, underscored the irreplaceable human connection in creativity.

🏥 AI in Healthcare

- Dr. Adam Oskowitz discussed Doctronic's AI-native care platform, which connects users to licensed doctors for consultations and prescription renewals.

- The platform's efficiency allows doctors to see more patients per hour, addressing the supply-demand mismatch in healthcare.

- A pilot program in Utah enables AI-driven prescription renewals, showcasing the potential for automation in medical services.

AI-generated content may not be accurate or complete and should not be relied upon as a sole source of truth.

📋 Episode Description

(01:22) - SpaceX's Lunar Mass Driver

(41:12) - 𝕏 Timeline Reactions

(54:37) - AI Coming for Zuck's Job

(58:17) - The Great Peptide Debate w/ Martin Shkreli & Max Marchione. Martin Shkreli, often referred to as the "Pharma Bro," is an American investor and former pharmaceutical executive known for his controversial decision to drastically increase the price of the life-saving drug Daraprim. In the conversation, Shkreli expresses skepticism about the growing popularity of peptides, attributing it to psychological factors like identity control and distrust of institutions. He emphasizes the importance of adhering to established pharmaceutical practices and regulatory frameworks to ensure drug safety and efficacy. Max Marchione is the co-founder of Superpower, a health optimization platform focused on proactive, data-driven care and longevity. He works at the intersection of consumer health, diagnostics, and software, building tools that give users deeper visibility into their biology and long-term health.

(01:31:35) - Mitchell Green, founder and managing partner of Lead Edge Capital, discusses the firm's recent closure of its $3.5 billion Fund 7, highlighting the strong interest from both existing and new limited partners. He emphasizes Lead Edge's unique approach, leveraging a diverse LP base of world-class executives and entrepreneurs to support portfolio companies through customer introductions, recruiting, and advisory roles. Green also addresses the resilience of the software industry, countering notions of a "SaaS apocalypse" by underscoring the enduring value and stickiness of enterprise software solutions.

(01:43:28) - Shane Hegde, co-founder and CEO of Air, a creative operations platform, discusses the company's recent initiatives, including a new ad campaign in The New York Times and their most significant product release to date. He emphasizes that while AI is a powerful tool, it cannot replace the deeply subjective and perfection-driven nature of creative work. Hegde introduces five new features launching tomorrow: access to 50 AI models within Air, a canvas editor for asset manipulation, AI agents for automated edits, a context layer to maintain brand consistency, and a shift to usage-based pricing.

(01:52:53) - Dr. Adam Oskowitz, co-founder and Chief Medical Officer of Doctronic, discusses their AI-native care platform that offers free, 24/7 health consultations, connecting users to licensed doctors across all 50 states for $39 per visit. He highlights the platform's efficiency, enabling doctors to see more patients per hour compared to traditional telehealth services, and mentions a pilot program in Utah where their AI system can renew prescriptions without direct physician involvement. Additionally, Dr. Oskowitz notes that the platform's ease of use encourages users to seek care they might otherw